Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP-TOO
NCT02928497Terminated
- Sponsor
- Boston Scientific Corporation
- Start
- Feb 2017
- Primary completion
- Sep 2025
- Countries
- 9
01
Overview
Randomised, open-label trial in stroke (2 arms), sponsored by Boston Scientific Corporation. Primary endpoints: Primary 7-Day Device/Procedural Safety Endpoint and Ischemic Stroke or Systemic Embolism at 5 years. Started Feb 2017; status: terminated.
02
Conditions
stroke
Beyond the preview
Go deeper on NCT02928497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928497.